Neutralizing antibody of anti-Omicron mutant strain and application of neutralizing antibody

By designing and preparing neutralizing antibodies against Omicron mutant strains, the problem of the resistance of existing vaccine neutralizing antibodies to the new coronavirus mutant strains is solved, and the strong neutralization effect on a variety of new coronavirus mutant strains is achieved, and the antibody preparation process is achieved. Simple, conservative in combination with epitopes.

CN118978588AInactive Publication Date: 2024-11-19SUN YAT SEN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411235957.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-04
Publication Date
2024-11-19
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing vaccine-induced neutralizing antibodies are resistant to the Omicron mutant strain of the new coronavirus mutant strain, leading to the occurrence of breakthrough infections, and it is necessary to develop broad-spectrum neutralizing antibodies that can effectively neutralize a variety of new coronavirus mutant strains.

Method used

A neutralizing antibody against Omicron mutant strain was designed, and variable region sequences of heavy and light chains were obtained through flow sorting and enzyme cleavage, and expression plasmids were constructed and expressed in host cells to prepare effective blocking. A full human antibody that binds the new coronavirus RBD to the host receptor protein ACE2.

Benefits of technology

This neutralizing antibody has a strong broad-spectrum neutralization effect on the popular new crown mutant strains XBB.1.5, EG.5.1, BA.2.86, JN.1 and KP.2, and the preparation process is simple and fast. The binding of the antibody to RBD is carried out. The epitope is relatively conservative and has strong neutralization ability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118978588A_ABST
    Figure CN118978588A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biology, in particular to a neutralizing antibody of an anti-Omicron mutant strain and application of the neutralizing antibody. The neutralizing antibody provided by the invention can effectively block the combination of the new coronavirus RBD and the host receptor protein ACE2. Through verification, the neutralizing antibody prepared by the invention has a strong broad-spectrum neutralizing effect on popular new crown mutants (XBB.1. 5, EG.5.1, BA.2.86, JN.1 and KP.2), and meanwhile, simulation structure analysis shows that binding epitopes of the neutralizing antibody and RBD are relatively conservative. The neutralizing antibody provided by the invention is simple and rapid in preparation process, is a fully humanized antibody, and has no immunogenicity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, and in particular to a neutralizing antibody against Omicron mutant strains and an application thereof. Background Art

[0002] COVID-19 is a respiratory infection caused by a new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is a virus that is particularly amenable to control by vaccination, such as mRNA vaccines and inactivated vaccines, which have achieved stunning success in booster-stage protection studies. This success is at least in part due to the ability of different models to induce strong neutralizing antibody (NAB) responses. However, some variants of concern (VOCs) have emerged that show significant resistance to NAB responses induced by infection and vaccination, and current vaccines apparently remain largely effective in preventing hospitalization and death caused by VOCs. However, as vaccine-induced NAB responses naturally decline, breakthrough infections also occur from time to time, and there is concern that these infections may become more common, potentially more clinically severe, and with the emergence of more pathogenic and resistant VOCs.

[0003] Therefore, VOCs viruses have prompted people to look for more diverse and effective NABs and vaccines. In fact, NABs have now been isolated directly from people who have recovered from coronavirus infection, or more specific and broad NABs have been produced through antibody engineering. Ideally, a large number of NABs will provide more options for the use of such antibodies for prevention and treatment. For example, broad-spectrum neutralizing antibodies against HIV and influenza viruses, as well as broad-spectrum neutralizing antibodies that can neutralize a variety of closely related viruses, such as antibodies that neutralize pneumoviruses and multiple viruses, and antibodies that can simultaneously neutralize dengue virus and Zika virus. Compared with some specific antibodies against a single virus, the advantage of broad-spectrum antibodies is that the antigenic epitopes they target are highly conserved and not easy to mutate, and they may also have the ability to neutralize unknown but similar viruses that may break out in the future.

[0004] In addition, SARS-CoV-2 is a positive-stranded single-stranded RNA virus. RNA viruses are characterized by a high mutation rate and the accumulation of mutations over time. This accumulation of mutations is the main driving force for viral evolution and genomic variation, thereby evading host immunity and developing drug resistance (Duffy S, PLoS Biol, 2018 08; 16(8)). The current Omicron mutants evolve particularly quickly, and the current vaccines are apparently still largely effective in preventing hospitalization and death caused by VOCs. However, due to the natural decline in vaccine-induced NAB responses, breakthrough infections also occur from time to time. The biggest feature of the new coronavirus mutants is that they can escape vaccine immunity and monoclonal antibodies. At present, the new coronavirus Omicron mutants have become resistant to multiple new coronavirus monoclonal antibodies that are on the market and in clinical trials. Therefore, it is necessary to discover potent and broad-spectrum neutralizing antibodies that can resist the escape of new coronavirus mutants to deal with the current epidemic mutants. Summary of the invention

[0005] The purpose of the present invention is to overcome the shortcomings of the prior art and provide a neutralizing antibody against Omicron mutants, which has a strong and broad-spectrum neutralizing effect on the prevalent new coronavirus mutants.

[0006] To achieve the above object, the technical solution adopted by the present invention is:

[0007] In the first aspect, the present invention provides a neutralizing antibody against Omicron mutant strains, the neutralizing antibody comprising a heavy chain and a light chain; in the heavy chain variable region CDR of the neutralizing antibody, the amino acid sequence of CDR1 is shown as SEQ ID NO: 1, the amino acid sequence of CDR2 is shown as SEQ ID NO: 2, and the amino acid sequence of CDR3 is shown as SEQ ID NO: 3; in the light chain variable region CDR of the neutralizing antibody, the amino acid sequence of CDR1 is shown as SEQ ID NO: 4, the amino acid sequence of CDR2 is shown as SEQ ID NO: 5, and the amino acid sequence of CDR3 is shown as SEQ ID NO: 6.

[0008] The structure of antibody molecules can be divided into two parts: constant region and variable region. In the variable region, a small part of amino acid residues change particularly strongly, and the residue composition and arrangement order of these amino acids are more prone to variation. This region is called hypervariable region (HVR). There are three hypervariable regions in the V region of the L chain and H chain. Because they can form precise complementarity with antigenic determinants in spatial structure, hypervariable regions are also called complementarity determining regions (CDR). The complementary determining region can form precise complementarity with antigenic determinants in spatial structure. The neutralizing antibody of the present invention (hereinafter referred to as SA-3) contains 3 heavy chain CDR regions and 3 light chain CDR regions. After design, the neutralizing antibody obtained can effectively block the binding of the new coronavirus RBD to the host receptor protein ACE2. It has been verified that the neutralizing antibodies prepared by the present invention have a strong and broad-spectrum neutralizing effect on the popular new coronavirus mutant strains (XBB.1.5, EG.5.1, BA.2.86, JN.1 and KP.2). At the same time, simulation structural analysis shows that the binding epitope of the neutralizing antibody with RBD is relatively conserved.

[0009] Preferably, the amino acid sequence of the heavy chain variable region CDR is shown in SEQ ID NO:7; and the amino acid sequence of the light chain variable region CDR is shown in SEQ ID NO:8.

[0010] Preferably, the gene sequence encoding the heavy chain variable region CDR is shown as SEQ ID NO: 9, and the gene sequence encoding the light chain variable region CDR is shown as SEQ ID NO: 10.

[0011] Preferably, in the neutralizing antibody, the full-length amino acid sequence of the heavy chain is shown as SEQ ID NO: 11, and the full-length amino acid sequence of the light chain is shown as SEQ ID NO: 12.

[0012] The method for preparing the above-mentioned neutralizing antibody against Omicron mutant comprises the following steps:

[0013] (1) Memory B cells specific for the SARS-CoV-2 S protein were sorted out by flow cytometry, and the Ig variable region sequences of memory B cells specific for the SARS-CoV-2 S protein were amplified to obtain specific PCR products;

[0014] (2) using restriction endonucleases to digest the specific PCR product, and connecting the digested specific PCR product to a plasmid to obtain an expression plasmid;

[0015] (3) The expression plasmid is transformed into competent cells, and a single clone is selected for culture to obtain heavy chain plasmid and light chain plasmid; the heavy chain plasmid and light chain plasmid are transfected into host cells, and after inducing expression, the purified antibody is collected.

[0016] The preparation process of the neutralizing antibody against the Omicron mutant strain of the present invention is simple and rapid, and the obtained neutralizing antibody is a fully human antibody with no immunogenicity.

[0017] Preferably, the restriction endonuclease comprises at least one of AgeI-HF, SalI-HF, BsiWI-HF, and XhoI.

[0018] In a second aspect, the present invention provides a nucleic acid molecule encoding the above-mentioned neutralizing antibody against Omicron mutant strain.

[0019] In a third aspect, the present invention provides an expression vector comprising the above nucleic acid molecule.

[0020] Preferably, the expression vector comprises at least one of an IgH vector, an Igκ vector, and an Igλ vector.

[0021] Preferably, the IgH vector is AbVec2.0-IGHG1; the Igκ vector is AbVec1.1-IGKC; and the Igλ vector is AbVec1.1-IGLC2-XhoI.

[0022] In a fourth aspect, the present invention provides a host cell comprising the above nucleic acid molecule or the above expression vector.

[0023] Preferably, the host cell comprises 293F cell.

[0024] In a fifth aspect, the present invention provides the use of the above-mentioned neutralizing antibodies, nucleic acid molecules or expression vectors against Omicron mutants in the preparation of reagents or drugs for preventing or treating novel coronavirus infection.

[0025] Preferably, the new coronavirus includes at least one of SARS-CoV-2, new coronavirus mutant strains XBB.1.5, EG.5.1, BA.2.86, JN.1, and KP.2.

[0026] The beneficial effects of the present invention are:

[0027] The present invention provides a neutralizing antibody against Omicron mutants and its application. The neutralizing antibody of the present invention can effectively block the binding of the new coronavirus RBD to the host receptor protein ACE2. It has been verified that the neutralizing antibody prepared by the present invention has a strong and broad-spectrum neutralizing effect on the popular new coronavirus mutants (XBB.1.5, EG.5.1, BA.2.86, JN.1 and KP.2), and the simulation structure analysis shows that the binding epitope of the neutralizing antibody to RBD is relatively conservative. The preparation process of the neutralizing antibody described in the present invention is simple and rapid, and it is a fully human antibody with no immunogenicity. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 This is a graph showing the binding activity results of the neutralizing antibodies against the Omicron mutant strain described in the present invention with SARS-CoV-2S1, S2, RBD and NTD.

[0029] Figure 2 This is a graph showing the competitive ELISA results between the neutralizing antibody against the Omicron mutant strain described in the present invention and hACE2.

[0030] Figure 3 This is a graph showing the results of cross-neutralization between the neutralizing antibody against Omicron mutants of the present invention and various Omicron mutants.

[0031] Figure 4 This is a graph showing the results of the neutralization of the anti-Omicron mutant strain neutralizing antibodies against SARS-CoV-2, XBB.1.5, EG.5.1, and JN.1 live viruses.

[0032] Figure 5 This is a simulated structural diagram of the neutralizing antibody and RBD against the Omicron mutant strain described in the present invention. DETAILED DESCRIPTION

[0033] In order to better illustrate the purpose, technical solutions and advantages of the present invention, the present invention will be further described below in conjunction with specific embodiments.

[0034] In the following examples, the experimental methods used are conventional methods unless otherwise specified, and the materials, reagents, etc. used are all available from commercial sources unless otherwise specified.

[0035] The sources of reagents or instruments used in the present invention are:

[0036] 10% fetal bovine serum (FBS): Gibco, catalog number: 10270-106; 1640 medium: Gibco, catalog number: C11875500CP; Live / dead: ThermoFisher, catalog number: L34962; CD3: BD Biosciences, catalog number: 612752; CD19: Biolegend, catalog number: 302230; IgD: Biolegend, catalog number: 348240; CD27: Biolegend, catalog number: 356412; IgG: BD Biosciences, catalog number: 555787; Alexa FluorTM 488 protein labeling kit: ThermoFisher, catalog number: A20181; SARS-CoV-2S ECD protein: Sino Biological, Catalog No.: 40589-V08B1; Random Primer: ThermoFisher, Catalog No.: SO181; RNAsin: Promega, Catalog No.: N2515; 5×RT buffer: ThermoFisher, Catalog No.: 18090050; Reverse transcriptase: ThermoFisher, Catalog No.: 18090050; 10×PCR buffer: QIAGEN, Catalog No.: 203207; HotStarTaq: QIAGEN, Catalog No.: 203207; Agarose gel DNA recovery kit: Tiangen, Catalog No.: DP209-03; CutSmart buffer: NEB, Catalog No.: B7204S; T4 DNA ligase buffer: NEB, Catalog No.: M0202L; T4 DNA ligase: NEB, Catalog No.: M0202L; AbVec2.0-IGHG1: AddGene, Catalog No.: 80795; AbVec1.1-IGKC: AddGene, Catalog No.: 80796; AbVec1.1-IGLC2-XhoI: AddGene, Catalog No.: 99575; DH5α competent cells: Tiangen, Catalog No.: CB101-02; TB medium: ThermoFisher, Catalog No.: 22711022; FreeStyle TM 293 expression medium: Gibco, catalog number: 12338018; Polyethylenimine (PEI): Polysciences, catalog number: 23996-2; OptiPRO TMSMF medium: ThermoFisher, Catalog No.: 12309019; 0.22μm filter: JET, Catalog No.: FPE204030; AgeI-HF: Catalog No. R3552L; SalI-HF: Catalog No. R3138L; BsiWI-HF: Catalog No. R3553L; XhoI: Catalog No. R0146L; Endotoxin-free plasmid miniprep kit: Tiangen, Catalog No.: DP118-02; SARS-CoV-2 S protein: SinoBiological, Catalog No.: 40589-V08H4; S1 protein: Sino Biological, Catalog No.: 40591-V08H; S2 protein: Sino Biological, Catalog No.: 40590-V08B; RBD protein: Sino Biological, Catalog No.: 40592-V08B; NTD protein: Sino Biological, Catalog No.: 40591-V41H; BSA: Sigma, Catalog No.: V900933; Anti-human IgG antibody: Jacksonimmunoresearc, Catalog No.: 109-035-003; TMB colorimetric solution: ThermoFisher, Catalog No.: 002023; VarioskanFlash full wavelength scanning multi-function reader: ThermoFisher Scientific; ELISA plate reader: Bio-tek, EL-808; ACE2-AVI: Sino Biological, Catalog No.: 10108-H27B-B; SA-HRP: Solebo, Catalog No.: SE068; Plasmid PNL4-3: Genebank, AF324493.2; Opti-MEM TM : ThermoFisher, catalog number: 31985062; DMEM culture medium: Gibco, catalog number: 11995065; cell lysis buffer: Promega, catalog number: E153A; luciferase detection reagent: Promega, catalog number: E1501; S protein rabbit monoclonal antibody: China Biological, 40143-T62; goat anti-rabbit antibody (H+L): Jackson, 111-035-144; KPL TrueBle peroxidase substrate: SeraCare Life Science, 5510-0030.

[0037] The present invention relates to the sequence of the antibody:

[0038]

[0039]

[0040]

[0041] Example 1: Neutralizing antibodies against Omicron mutants and their preparation

[0042] This embodiment provides a neutralizing antibody against Omicron mutant strains; the neutralizing antibody comprises a heavy chain and a light chain; in the heavy chain variable region CDR of the neutralizing antibody, the amino acid sequence of CDR1 is shown as SEQ ID NO: 1, the amino acid sequence of CDR2 is shown as SEQ ID NO: 2, and the amino acid sequence of CDR3 is shown as SEQ ID NO: 3; in the light chain variable region CDR of the neutralizing antibody, the amino acid sequence of CDR1 is shown as SEQ ID NO: 4, the amino acid sequence of CDR2 is shown as SEQ ID NO: 5, and the amino acid sequence of CDR3 is shown as SEQ ID NO: 6.

[0043] The amino acid sequence of the heavy chain variable region CDR is shown in SEQ ID NO: 7; the amino acid sequence of the light chain variable region CDR is shown in SEQ ID NO: 8.

[0044] The gene sequence encoding the heavy chain variable region CDR is shown in SEQ ID NO:9, and the gene sequence encoding the light chain variable region CDR is shown in SEQ ID NO:10.

[0045] In the neutralizing antibody, the full-length amino acid sequence of the heavy chain is shown in SEQ ID NO: 11, and the full-length amino acid sequence of the light chain is shown in SEQ ID NO: 12.

[0046] This embodiment also provides a method for preparing the neutralizing antibody against the Omicron mutant, comprising the following steps:

[0047] 1. Flow cytometry single cell sorting of SARS-CoV-2 specific memory B cells

[0048] 1.1 Collect peripheral blood from patients who have recovered from SARS-CoV-2 infection and isolate PBMCs (freeze in liquid nitrogen for future use and resuscitate from liquid nitrogen when needed);

[0049] 1.2 Add complete culture medium (1640 medium containing 10% fetal bovine serum) and incubate at 37°C overnight;

[0050] 1.3 Then the cells were stained with Live / dead, CD3, CD19, IgD, CD27, IgG and SARS-CoV-2S probes, which were Alexa Fluor TM SARS-CoV-2S ECD protein labeled with 488 protein labeling kit; Live / dead flow sorting - CD3 -CD19 + IgD - CD27 + IgG + As well as B cells positive for SARS-CoV-2S probe, SARS-CoV-2S protein-specific Memory B cells were obtained.

[0051] 2. Amplify the SARS-CoV-2-specific memory B cell Ig variable region sequence (refer to the literature: Wardemann, H et al., Methods Mol Biol, 2019.1956: p.105-125.).

[0052] 2.1 Prepare cell lysis buffer and add it to a 96-well PCR plate. The configuration system is shown in Table 1 below:

[0053] Table 1

[0054]

[0055]

[0056] 2.2 Add the SARS-CoV-2S protein-specific memory B cells sorted in step (1.3) to the 96-well PCR plate containing the cell lysate; place the 96-well PCR plate on dry ice and quickly freeze the lysed cells; incubate at 68°C for 1 minute and place on ice;

[0057] 2.3 Configure the cDNA synthesis system as shown in Table 2 below:

[0058] Table 2

[0059] Components volume 5×RT buffer 2.8μL 100mM DTT 1.05μL 25mM dNTP 0.5μL 40U / μL RNAsin 0.2μL 200U / μL reverse transcriptase 0.25μL Nuclease-free water 2.2μL

[0060] PCR amplification, PCR reaction conditions are: 42°C, 5 min; 25°C, 10 min; 50°C, 60 min; 94°C, 5 min, to obtain antibody variable region cDNA.

[0061] 2.4 The first round of amplification of the Ig variable region, the reaction system is shown in Table 3 below:

[0062] Table 3

[0063] Components volume water 29.82μL 10×PCR buffer 4μL 5'First PCR primer mix 1.3μL 3'First PCR primer mix 1.3μL 25mM dNTP 0.4μL 5U / μL HotStarTaq 0.18μL cDNA: Here is the cDNA obtained in step (2.3) 3μL

[0064] The above 5'First PCR primer mix and 3'First PCR primer mix refer to the literature: Wardemann, H et al., Methods Mol Biol, 2019.1956: p.105-125.

[0065] PCR amplification, PCR reaction conditions are: 94°C, 15 min pre-denaturation; 94°C, 30 s; 58°C, 30 s (IgH and Igκ) or 60°C, 30 s (Igλ); 72°C, 55 s amplification (50 cycles); 72°C, 10 min to obtain the first round of PCR amplification products.

[0066] 2.5 The second round of amplification of the variable region of Ig, the reaction system is shown in Table 4 below:

[0067] Table 4

[0068] Components volume water 29.32μL 10×PCR buffer 4μL 5'Second PCR primer mix 1.3μL 3'Second PCR primer mix 1.3μL 25mM dNTP 0.4μL 5U / μL HotStarTaq 0.18μL The first round of PCR amplification products 3.5μL

[0069] Among them, the above-mentioned 5'Second PCR primer mix and 3'Second PCR primer mix are both referenced from the literature: Wardemann, H et al., Methods Mol Biol, 2019.1956: p.105-125.

[0070] PCR amplification, PCR reaction conditions are: 94°C, 15 min pre-denaturation; 94°C, 30 s; 58°C, 30 s (IgH and Igκ) or 60°C, 30 s (Igλ); 72°C, 45 s amplification (50 cycles); 72°C, 10 min to obtain the second round of PCR amplification products.

[0071] The second-round PCR amplification product was recovered using an agarose gel DNA recovery kit.

[0072] 2.6Ig variable region specific amplification, the reaction system is shown in Table 5 below:

[0073] Table 5

[0074] Components volume water 27.2μL 10×PCR buffer 4μL 5'Specific PCR primer mix 2μL 3'Specific PCR primer mix 2μL 25mM dNTP 0.4μL 5U / μL HotStarTaq 0.2μL The first round of PCR amplification products 4.2μL

[0075] Among them, the above-mentioned 5'Specific PCR primer mix and 3'Specific PCR primer mix refer to the literature: Wardemann, H et al., Methods Mol Biol, 2019.1956: p.105-125.

[0076] PCR reaction conditions: 94°C, 15 min pre-denaturation; 94°C, 30 s; 58°C, 30 s (IgH and Igκ) or 60°C, 30 s (Igλ); 72°C, 45 s amplification (50 cycles); 72°C, 10 min.

[0077] The specific PCR product was recovered by an agarose gel DNA recovery kit and detected by agarose gel electrophoresis.

[0078] 3. Construction of expression plasmid, in vitro transfection, expression and purification of neutralizing antibodies

[0079] 3.1 Construction of expression plasmid

[0080] 3.1.1 Take 30.4 μL of each of the above specific PCR products (IgH, Igκ and Igλ), add 3.4 μL of CurtSmart buffer and mix well to obtain the corresponding mixture A;

[0081] The enzyme digestion system mixture is prepared according to different PCR products, as shown in Table 6 below:

[0082] Table 6

[0083] IgH Igκ Igλ 5.3 μL water 5.3 μL water 5.3 μL water 0.6 μL CutSmart Buffer 0.6 μL CutSmart Buffer 0.6 μL CutSmart Buffer 0.05μL AgeI-HF 0.05μL AgeI-HF 0.05μL AgeI-HF 0.05 μL SalI-HF 0.05μL BsiWI-HF 0.05 μL XhoI

[0084] The above-mentioned AgeI-HF, SalI-HF, BsiWI-HF and XhoI are NEB restriction endonucleases; the product numbers are R3552L (AgeI-HF), R3138L (SalI-HF), R3553L (BsiWI-HF) and R0146L (XhoI), respectively.

[0085] The corresponding enzyme digestion system mixtures were added to the mixture A, and the digestion was carried out at 37° C. for 2 h. The digested products were recovered using an agarose gel DNA recovery kit.

[0086] 3.1.2 Ligation The specific PCR product after enzyme digestion was connected to the corresponding vector at 16°C overnight. The connection system is shown in Table 7 below:

[0087] Table 7

[0088] Components volume Specific PCR products after restriction digestion (IgH or Igκ or Igλ) 8μL Expression vector (IgH vector or Igκ vector or Igλ vector) 0.5μL T4 DNA Ligase Buffer 1μL T4 DNA ligase 0.5μL

[0089] The above-mentioned IgH vector is AbVec2.0-IGHG1, the Igκ vector is AbVec1.1-IGKC, and the Igλ vector is AbVec1.1-IGLC2-XhoI.

[0090] Add the above overnight ligation product to a centrifuge tube containing 100 μL DH5α competent cells and place it on ice for 30 minutes; then place it in a 42°C water bath and heat shock for 90 seconds. Take it out and place it on ice for 3-5 minutes, then add 900 μL TB culture medium; after shaking and culturing for 45-60 minutes, centrifuge it at 6000rpm for 1 minute; aspirate 800 μL supernatant, and use the remaining liquid to blow and mix the bacteria (derived from the above competent cells) to obtain a bacterial suspension; evenly spread it on an agar plate with ampicillin; invert the agar plate in a 37°C bacterial incubator and culture it for 16 hours; pick a single full colony on the agar plate and send it to the company for sequencing together with the second round of PCR products; select colonies that match the second round of PCR product sequences 100%, use the endotoxin-free plasmid mini-extraction kit to extract the plasmids, and obtain the heavy chain plasmid and light chain plasmid respectively.

[0091] 3.2 In vitro transfection and expression

[0092] Use FreeStyle one day before transfection TM 293 expression medium: adjust the 293F cell density to 1×10 6 Prepare PEI mixture: Add Polyethylenimine (PEI) to OptiPRO TM The concentration during transfection was 4 μg / mL in SMF medium.

[0093] Prepare plasmid mixture: Add the extracted paired heavy chain plasmid and light chain plasmid into OptiPRO TM SFM medium was added to mix well to make the total plasmid concentration at the time of transfection 1μg / mL; finally, the PEI mixture was added to the plasmid mixture and gently mixed to form a transfection mixture system, and then allowed to stand at room temperature for 20 minutes. The transfection mixture system was added to 293F cells (the cells were counted on the day of transfection and fresh FreeStyle TM 293 expression medium: adjust the 293F cell density to 2 × 10 6 pc / mL), shake gently to mix, and place in 8% CO 2 The suspension culture was performed in a 37°C suspension incubator at 125 rpm for 7 days to obtain a suspension culture solution.

[0094] 3.3 Purification of neutralizing antibodies

[0095] The transfected suspension culture medium obtained in step (3.2) was centrifuged at 4000 rpm for 15 min to collect the expression supernatant, which was then filtered using a 0.22 μm filter.

[0096] Open The protein purifier was used to balance the Protein A column with PBS at a flow rate of 3 mL / min; the filtered expression supernatant was then loaded onto the Protein A column at a flow rate of 3 mL / min; non-specific binding proteins on the Protein A column were washed away with PBS at a flow rate of 3 mL / min; antibodies bound to the Protein A column were eluted with a glycine buffer at pH 3.0 at a flow rate of 1 mL / min; the eluate was collected to obtain purified neutralizing antibodies against the Omicron mutant strain.

[0097] Example 2: ELISA to determine the target of neutralizing antibodies binding to SARS-CoV-2 spike protein

[0098] SARS-CoV-2 S protein, S1 protein, S2 protein, RBD protein, and NTD protein were coated on the ELISA plate at a concentration of 2 μg / mL (100 μL / well) respectively; after incubation at 4°C overnight, unbound proteins were washed away with 1×PBST; the blocking solution containing 2% FBS and 2% BSA was used for blocking at room temperature for 2 h; after washing away the blocking solution with 1×PBST, the neutralizing antibody purified in Example 1 and the control antibody were added to the ELISA plate at a concentration of 1 μg / mL and incubated at 37°C for 1 h; after washing away the unbound antibody with 1×PBST, RHP-labeled anti-human IgG antibody was added and incubated at 37°C for 1 h; after washing away the unbound anti-human IgG antibody with 1×PBST, 100 μL TMB colorimetric solution was added and incubated at room temperature for 5 min; finally, 50 μL 1M sulfuric acid was added to terminate the reaction; the OD value was measured using a Varioskan Flash full-wavelength scanning multifunctional reader, and the OD value was used to reflect the binding strength of the antibody.

[0099] The results are as follows Figure 1 As shown, the neutralizing antibody (SA-3) obtained by the present invention exhibits strong binding ability to both SARS-CoV-2S1 and RBD proteins, but has no binding ability to SARS-CoV-2S2, indicating that the neutralizing antibody is an antibody targeting RBD.

[0100] Example 3: Competitive experiment between neutralizing antibodies and hACE2

[0101] The experimental process is:

[0102] (1) SARS-CoV-2 RBD was coated on a 96-well plate at 2 μg / mL (100 μL / well) at room temperature or at 4°C overnight.

[0103] (2) Wash the plate five times with phosphate buffered saline (PBS) containing 0.05% Tween-20, and block and culture with 5% skim milk for 2 to 4 hours at room temperature.

[0104] (3) After washing five times with PBST (PBS containing 0.05% Tween-20), the neutralizing antibody prepared in Example 1 was diluted to different concentrations (0.1 μg / mL, 1 μg / mL, 10 μg / mL), added to a microplate, 100 μL per well, and incubated at 37°C for 1 hour.

[0105] (4) After washing five times with PBST (PBS containing 0.05% Tween-20), 100 μL of 1 μg / mL ACE2-AVI was added to each well and incubated at 37°C for 1 hour.

[0106] (5) After washing five times with PBST (PBS containing 0.05% Tween-20), SA-HRP was diluted at 1:2000 to obtain SA-HRP diluent, 100 μL SA-HRP diluent was added to each well, incubated at 37°C for 1 h, and washed 5 times.

[0107] (6) After adding 100 μL of tetramethylbenzidine substrate (TMB) to each well and reacting in the dark for 5 to 8 min, 50 μL of 1 M concentrated sulfuric acid solution was added to each well to terminate the reaction. The absorbance value was measured at 450 nm (OD450) using an ELISA plate reader.

[0108] The results are as follows Figure 2 As shown, the neutralizing antibody SA-3 obtained in the present invention exhibits good competitive ability against hACE2.

[0109] Example 4: Virus Neutralization Experiment

[0110] 1. Pseudovirus Encapsulation

[0111] 1.1 One day before infection, 5 × 10 6 293T cells were seeded into a 10 cm cell culture dish at a density of cells / well.

[0112] 1.2 The gene sequence encoding the S protein of SARS-CoV-2 or Omicron mutant strain was synthesized by Nanjing GenScript and inserted into the pcDNA3.1 vector to obtain a synthetic plasmid. Among them, the gene numbers of the above-mentioned Omicron mutant strains are: SARS-CoV-2 (Genebank: YP_009724390.1), BA.2 (EPI_ISL_6795834.2), BA.3 (EPI_ISL_7605589), BA.4 / 5 (EPI_ISL_12268493.2), BA.2.75 (GenBank: OP703311.1), BF.7 (EPI_ISL_15693205), BQ.1 (EPI_ISL_15693263), XBB.1.5 (EPI_ISL_16292655), EG.5.1 (EPI_ISL_17700360), JN.1 (EPI_ISL_18727440) and KP.2 (EPI_ISL_19201332).

[0113] 1.3 Preparation of plasmid mixture: Add the plasmid synthesized by the company in step (1.2) and plasmid PNL4-3 (Genebank: AF324493.2) in a mass ratio of 1:3 to Opti-MEM TM Mix well in the culture medium to make the total plasmid concentration 1 μg / mL; prepare PEI mixture: add Polyethylenimine (PEI) to Opti-MEM TM The PEI mixture was added to the plasmid mixture and gently mixed to form a transfection mixture system, which was allowed to stand at room temperature for 20 minutes.

[0114] 1.4 Discard the 293T cell culture medium in the cell culture dish in step (1.1), add the transfection mixture system in step (1.3) to the 293T cells, and place them at 37°C with 5% CO 2 Cultured in a cell culture incubator for 6 h.

[0115] 1.5 Aspirate the transfection mixture and replace with fresh DMEM medium containing 10% FBS and place at 37°C and 5% CO 2 After culturing in a cell culture incubator for 72 hours, the supernatant was collected after centrifugation at 12000 rpm for 15 minutes. The supernatant was the packaged pseudovirus.

[0116] 2. Pseudovirus neutralization experiments detected the half inhibitory concentration (IC) of the neutralizing antibodies purified in Example 1 against the new coronavirus SARS-CoV-2 and the new coronavirus BA.2, BA.3, BA.4 / 5, BA.2.75, BF.7, BQ.1, XBB.1.5, EG.5.1, JN.1and KP.2 mutants 50 )

[0117] 2.1 One day before infection, 0.8×10 5 293T / hACE2 cells were seeded into a 96-well plate at a density of 100 μL / mL, and the culture medium used was DMEM containing 10% FBS.

[0118] 2.2 On the day of infection, the neutralizing antibody obtained in Example 1 was diluted to different concentrations (the neutralizing antibody was diluted with DMEM culture medium containing 10% FBS into antibody dilutions of different concentrations: 10, 3.33, 1.111, 0.3704, 0.1235, 0.0412, 0.0137, 0.0046, 0.0015, 0.0005, 0.0002 and 0 μg / mL), respectively mixed with the packaged pseudovirus of step (1.5), diluted to obtain multiple groups of mixed solutions, and incubated at 37°C for 1 h.

[0119] 2.3 Discard the culture medium in the 96-well plate in step (2.1), add the mixed solution after incubation in step (2.2), and centrifuge at 800×g for 30 minutes; incubate in a 37°C cell culture incubator for 6-8 hours, discard the mixed solution, and add freshly prepared DMEM culture medium containing 10% FBS.

[0120] 2.4 After the cells were cultured for 48 hours, 50 μL of cell lysis solution was added to each well of the 96-well culture plate and lysed at 37°C for 2 minutes; the 96-well culture plate was then placed in a -40°C freezer for 30 minutes; after freezing, the 96-well culture plate was taken out and placed at 37°C for 3 minutes, and then centrifuged at 2000 rpm for 1 minute to obtain cell lysate; 40 μL of the above cell lysate was added to the 96-well black flat floor; 50 μL of luciferase detection reagent was added, and the OD value was measured using a Varioskan Flash full-wavelength scanning multifunctional reader (ThermoFisher); the neutralization inhibition rate was calculated according to formula (1); based on the results of the neutralization inhibition rate, the IC of the antibody was calculated using Prism8.0 software (GraphPad) 50 .

[0121] Neutralization inhibition rate = [1 - (OD value of the well with antibody and virus mixture - OD value of the blank well) / (OD value of the well without antibody and only virus - OD value of the blank well] × 100% - Formula (1)

[0122] The results are as follows Figure 3 As shown, the neutralizing antibody SA-3 of the present invention exhibits strong neutralizing ability against the new coronavirus SARS-CoV-2 and most Omicron mutant strains.

[0123] Example 5: Live virus neutralization experiment

[0124] 50 μL of the gradient dilution of the neutralizing antibody SA-3 obtained in Example 1 was mixed with 50 μL of SARS-CoV-2, XBB.1.5, EG.5.1, and JN.1 live viruses (200 focus-forming units), incubated at 37° C. for 1 h, transferred to a 96-well plate inoculated with Vero E6 cells, and cultured at 37° C. for 1 h for virus infection.

[0125] After infection, the virus solution was discarded and DMEM virus maintenance solution containing 1.2% (v / v) sodium carboxymethyl cellulose was added. After 24 hours, the cells were fixed with 4% (v / v) paraformaldehyde and 0.2% (v / v) TritonX-100 increased cell permeability. Immunostaining was performed with S protein rabbit monoclonal antibody and peroxidase-labeled goat anti-rabbit antibody (H+L), respectively. Finally, KPL TrueBle peroxidase substrate was used to display virus-infected lesions, and CTL Immuno Spot S6 (Ccell Technology Limited) was used to count the virus lesion units.

[0126] The results are as follows Figure 4 As shown, the neutralizing antibody SA-3 obtained in the present invention has good neutralizing activity against SARS-CoV-2, XBB.1.5, EG.5.1, and JN.1 live viruses.

[0127] Example 6: Simulation and prediction of the structure of neutralizing antibodies and BA.2.86 RBD

[0128] The structure of BA.2.86RBD (PDB: 8QSQ) was retrieved from the Protein Data Bank (PDB) for analysis. Antibody structure prediction and molecular docking analysis were performed using Alphafold 3 and HDCOK. Interface residues were identified using the InterfaceResidues script in PyMOL software. Structural analysis plots were generated by PyMOL v2.3.2.

[0129] The results are as follows Figure 5 As shown, the binding epitopes of neutralizing antibody SA-3 and BA.2.86RBD are K403, H445, Y449, Y453, P485, F489, Q492, G495, R497, Y500 and H504. These binding epitopes are relatively conservative epitopes and are outside the range of hotspot mutations.

[0130] In summary, the neutralizing antibodies prepared by the present invention can effectively block the binding of the SARS-CoV-2 RBD to the host receptor protein ACE2, and have strong neutralizing ability against a variety of Omicron mutant strains. Simulation structural analysis also shows that the binding epitope of the neutralizing antibody SA-3 and RBD is relatively conserved.

[0131] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the essence and scope of the technical solution of the present invention.

Claims

1. A neutralizing antibody against an Omicron mutant, characterized in that: The neutralizing antibody comprises a heavy chain and a light chain; in the heavy chain variable region CDR of the neutralizing antibody, the amino acid sequence of CDR1 is shown as SEQ ID NO: 1, the amino acid sequence of CDR2 is shown as SEQ ID NO: 2, and the amino acid sequence of CDR3 is shown as SEQ ID NO: 3; in the light chain variable region CDR of the neutralizing antibody, the amino acid sequence of CDR1 is shown as SEQ ID NO: 4, the amino acid sequence of CDR2 is shown as SEQ ID NO: 5, and the amino acid sequence of CDR3 is shown as SEQ ID NO:

6.

2. The neutralizing antibody against Omicron mutant according to claim 1, characterized in that The amino acid sequence of the heavy chain variable region CDR is shown in SEQ ID NO: 7; the amino acid sequence of the light chain variable region CDR is shown in SEQ ID NO:

8.

3. The neutralizing antibody against Omicron mutant according to claim 2, characterized in that The gene sequence encoding the heavy chain variable region CDR is shown in SEQ ID NO:9, and the gene sequence encoding the light chain variable region CDR is shown in SEQ ID NO:

10.

4. The neutralizing antibody against Omicron mutant according to claim 1, characterized in that In the neutralizing antibody, the full-length amino acid sequence of the heavy chain is shown in SEQ ID NO: 11, and the full-length amino acid sequence of the light chain is shown in SEQ ID NO:

12.

5. A nucleic acid molecule encoding the neutralizing antibody against the Omicron mutant strain according to any one of claims 1 to 4.

6. An expression vector comprising the nucleic acid molecule of claim 5.

7. The expression vector according to claim 6, characterized in that The expression vector comprises at least one of an IgH vector, an Igκ vector, and an Igλ vector.

8. A host cell comprising the nucleic acid molecule of claim 5 or the expression vector of claim 6.

9. Use of the neutralizing antibody against Omicron mutant strains according to any one of claims 1 to 4, the nucleic acid molecule according to claim 5, or the expression vector according to claim 6 in the preparation of an agent or drug for preventing or treating novel coronavirus infection.

10. The use according to claim 9, characterized in that The new coronavirus includes at least one of SARS-CoV-2, new coronavirus mutant strains XBB.1.5, EG.5.1, BA.2.86, JN.1, and KP.2.